Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02602301
Other study ID # oxytocin
Secondary ID
Status Active, not recruiting
Phase Phase 4
First received November 8, 2015
Last updated November 10, 2015
Start date November 2015
Est. completion date March 2016

Study information

Verified date November 2015
Source Kasr El Aini Hospital
Contact n/a
Is FDA regulated No
Health authority Egypt: Institutional Review Board
Study type Interventional

Clinical Trial Summary

Objective: To evaluate the relationship between intravenous (IV) infusion of oxytocin using either saline 0.9% or glucose 5% & neonatal Bilirubin & sodium level.

Study Design: A randomized case - controlled study. Setting: The Obstetrics and Gynecology casuality department of Kasr El Aini hospital (Cairo University - Egypt)


Description:

This prospective randomized case-controlled study was performed at the Obstetrics and Gynecology causality Department of Kasr El Aini University hospital, Cairo University, Egypt in the period from November 2015 to March 2016. The study was approved by the Hospital Ethical Committee. Informed consents were obtained from all patients after explanation of the aim of the study & the potential risks. The study was not supported by any pharmacological company.

327 multigravidas with singleton living healthy fetus presented to the casuality department with spontaneous onset of labour & gave birth through the vaginal route were enrolled in the study. They were randomized into 3 groups: group A that included 109 women in whom labour was augmented by IV infusion of oxytocin using isotonic saline 0.9%, group B that included 109 women in whom labour was augmented by IV infusion of oxytocin using glucose 5% & group C (control group) in which 109 women continued their labour course without any further augmentation.

Inclusion criteria included: maternal age between 20 & 35 years old, gestational age 37 to 40 weeks (confirmed by a reliable date for the last menstrual period and 1st trimester ultrasound scan), vertex presentation of the fetus & intact membranes. Women who had chronic or pregnancy induced diseases or any contraindication to vaginal delivery (e.g. malpresentation, contracted pelvis & placenta previa) were excluded. Additional exclusion criteria included rhesus (Rh) negative or (O) blood group mothers, prolonged labour (> 12h), fetal distress, instrumental delivery (forceps or vacuum extraction), abnormal fetal growth (IUGR or macrosomia), non-reassuring initial fetal CTG & epidural analgesia. Neonates with one or more of the following criteria were excluded: Apgar score < 5 or <7 at one minute or five minutes respectively, low birth weight (< 2.5 kg), birth trauma or abnormal G6PD enzyme levels.

For all patients, full history was taken followed by complete physical examination & obstetric ultrasound. Initial baseline CTG was done to confirm fetal wellbeing. Patient was then randomized to one of the three groups. 5 units oxytocin was placed in 500 cc of isotonic saline 0.9% or 5% glucose With the beginning of active phase (defined as fully effaced cervix with 3-4 cm dilatation), the investigator gave the patient either 5 units oxytocin placed in 500 cc of isotonic saline 0.9% (group A) or 5% glucose (group B). The rate of infusion in both groups was 2.5 mIU/min of oxytocin intravenous drip with the dose increased by 2.5 mIU/ml every 20min till effective uterine contractions establishment (defined as the presence of 3 forceful uterine contractions over 10 mins span). Amniotomy was done at cervical dilatation ≥ 6 cm if spontaneous rupture of membranes did not occur. Opioid analgesia was given after the amniotomy (meperidine hydrochloride 50 mg IM). Oral fluid intake was not restricted in all patients.

Participants were monitored in bed together with fetal wellbeing surveillance using continuous CTG monitoring. A partogram was maintained throughout labour and vaginal examinations were conducted and recorded every 2 hours.

Following fetal delivery, cord was clamped within 2 minutes from birth Sodium and initial bilirubin levels were measured in the cord. Umbilical cord blood samples (10 ml) were obtained from the placental site of divided umbilical cord into heparin test tubes and plasma was separated immediately. Sodium, initial haemtocrit & bilirubin levels were measured. All babies were breastfed. Neonatal capillary blood (obtained by heel prick) bilirubin and haemtocrit concentrations were remeasured on day 1 and 2. Sodium measurement was done using flame photometry while bilirubin level was determined using spectrophotometry.

Data collected included total volume of fluid & total oxytocin dose administered till delivery, neonatal Apgar score at birth (1 & 5 minutes), birth weight, cord sodium, haemtocrit & bilirubin levels at birth and neonatal plasma haemtocrit & bilirubin levels on day 1 & 2.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 327
Est. completion date March 2016
Est. primary completion date March 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 20 Years to 35 Years
Eligibility Inclusion Criteria:

- maternal age between 20 & 35 years old, gestational age 37 to 40 weeks (confirmed by a reliable date for the last menstrual period and 1st trimester ultrasound scan), vertex presentation of the fetus & intact membranes

Exclusion Criteria:

- Women who had chronic or pregnancy induced diseases or any contraindication to vaginal delivery (e.g. malpresentation, contracted pelvis & placenta previa) were excluded. Additional exclusion criteria included rhesus (Rh) negative or (O) blood group mothers, prolonged labour (> 12h), fetal distress, instrumental delivery (forceps or vacuum extraction), abnormal fetal growth (IUGR or macrosomia), non-reassuring initial fetal CTG

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic


Intervention

Drug:
Oxytocin
different oxytocin diluents and effect on fetal bilirubin&sodium levels.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Kasr El Aini Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary neonatal bilirubin level 11/2015 to March 2016 5 months. No
Secondary neonatal APGAR score 11/2015 to 3 /2015 5 months No
See also
  Status Clinical Trial Phase
Recruiting NCT06186349 - The Effect and Mechanism of Gene Variation on Neonatal Hyperbilirubinemia
Recruiting NCT04369313 - Effect of DCC on Neonatal Jaundice and Blood Gas Analysis in Infants Born to GDM Mothers N/A
Not yet recruiting NCT04585828 - Comparison of Double Pad Fiber Optic Device Versus Conventional Phototherapy N/A
Completed NCT02927093 - Clinical and Developmental Outcomes of Babies Who Became Yellow in the First Month of Life N/A
Unknown status NCT01340339 - Reverse Phototherapy With Super Light-emitting Diode(Super-LED) for Hyperbilirubinemia in Term and Late Preterm Infants Phase 4
Completed NCT02033096 - Observational Follow-up of Participants From Clinical Trial 64,185-202 (NCT00850993)
Recruiting NCT04218318 - Safe Threshold to Discontinue Phototherapy in Hemolytic Disease of Newborn N/A
Completed NCT00801619 - Bilicurves: Using Information Technology to Improve the Management of Neonatal Hyperbilirubinemia N/A
Active, not recruiting NCT05343403 - Parental Participation on the Neonatal Ward - the neoPARTNER Study
Completed NCT03880591 - Neonatal Hyperbilirubinaemia in the Democratic Republic of Congo
Completed NCT01599611 - Follow-up of Extreme Neonatal Hyperbilirubinemia in 5-10 Year Old Children: a Danish Population Based Study N/A
Recruiting NCT06399146 - Evaluation of Bilirubin Estimates in Newborns From Smartphone Digital Images in a Population in Botswana N/A
Completed NCT06018012 - MRA and ABR as Early Predictors of Bilirubin-Induced Neurologic Dysfunction in Full-term Jaundiced Neonates
Completed NCT03536078 - Home Phototherapy for Term Newborns With Icterus N/A
Withdrawn NCT00917007 - Measurement of Carboxyhemoglobin by Gas Chromatography as an Index of Hemolysis
Recruiting NCT00154960 - Establishing Novel Detection Techniques for Various Genetic-Related Diseases by Applying DHPLC Platform. N/A
Recruiting NCT02594904 - Efficacy of Yinzhihuang Oral Liquid on Indirect Bilirubin of Neonates With Glucose-6-phosphate Dehydrogenase Deficiency Phase 4
Completed NCT01746511 - Glycerin Suppositories to Reduce Jaundice in Premature Infants N/A
Completed NCT01470820 - Dose-response Relationship of Phototherapy for Hyperbilirubinaemia Using Diodes: is There a "Saturation Point" N/A
Completed NCT02361788 - Study on Newborn Babies With a Yellow Skin Color (Neonatal Jaundice Study)